Bicara Therapeutics Inc. (BCAX) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-28

Key Insights

Chief Medical Officer David Raben executed a net sell transaction, disposing of 5,500 shares at a weighted average price of $22.88 while simultaneously acquiring 5,500 shares at $3.79, resulting in a significant net cash inflow despite maintaining similar share count.
The sale was executed under a Rule 10b5-1 trading plan adopted on February 12, 2025, indicating this was a pre-planned transaction rather than opportunistic selling, which reduces concerns about sudden loss of confidence.
Raben's beneficial ownership decreased from 60,786 to 55,286 shares after the sale, representing a net reduction of approximately 9% of his previously held position, suggesting modest insider selling pressure.
The substantial price differential between purchase price ($3.79) and sale price ($22.88) suggests significant appreciation in the stock since the CMO's equity grants were issued, though the timing and methodology indicate pre-planned rebalancing rather than peak-selling.

Want the newest filings?

This analysis covers the filing from 2026-04-28. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-22

CFO Hyep Ivan executed a net sale of 9,200 shares on 04/21/2026 at a weighted average price of $23.00, generating approximately $211,614 in proceeds, indicating insider selling activity despite a simultaneously granted stock option award.
The insider simultaneously purchased 9,200 shares at $3.79 and sold the same quantity at $23.00 on the same day, suggesting execution of a pre-planned Rule 10b5-1 trading plan adopted on 02/13/2025, which limits inference about current market sentiment.
A stock option grant of 9,200 shares with exercise price of $3.79 was awarded, vesting over 4 years in quarterly installments, providing retention incentive but the substantial gap between exercise price and current trading price ($23.00) suggests the option has significant intrinsic value.

Filed: 2026-04-20

CEO Claire Mazumdar executed a significant stock sale of 15,000 shares on 04/20/2026 at an average price of $23.61, generating approximately $354,145 in proceeds, which represents a material reduction in her direct shareholdings.
The sale was executed under a Rule 10b5-1 trading plan adopted on February 12, 2025, indicating pre-planned and non-discretionary trading rather than reactive market timing, which reduces insider trading concerns.
Mazumdar simultaneously acquired 15,000 stock options on 04/20/2026 at an exercise price of $3.7898 with an expiration date of 08/08/2033, suggesting the company is actively granting equity incentives to retain leadership while the CEO liquidates shares.
The CEO's total direct common stock ownership decreased from 377,152 shares (post-acquisition) to 362,152 shares (post-sale), representing approximately a 4% reduction in her beneficial ownership position.

Filed: 2026-04-17

The reporting person, Ryan Cohlhepp, who is the President and COO of Bicara Therapeutics Inc. (BCAX), exercised 8,000 stock options and subsequently sold 12,500 shares of the company's common stock.
The sale of shares was conducted pursuant to a Rule 10b5-1 trading plan, indicating a pre-planned transaction.
The reported transactions suggest insider activity, which could be interpreted as a signal about the company's future prospects or the executive's personal financial needs.

Filed: 2026-03-26

David Raben, the Chief Medical Officer of Bicara Therapeutics, exercised 5,500 stock options at $3.7898 per share and immediately sold the same number of shares at a weighted average price of $18.9508 per share, indicating he may be monetizing some of his equity-based compensation.
Raben's transactions were conducted pursuant to a pre-arranged 10b5-1 trading plan, suggesting a degree of planning and structure around his trading activity.
The exercise and sale of options represent a relatively small portion of Raben's total beneficial ownership in Bicara, as he continues to hold 55,286 shares directly following the reported transactions.

Filed: 2026-03-24

The reporting person, Ivan Hyep, who is the Chief Financial Officer of Bicara Therapeutics Inc., exercised 9,200 stock options and then sold 9,200 shares of common stock on March 23, 2026.
The stock option exercise price was $3.7898 per share, and the shares were sold at a weighted average price of $18.5161 per share.
The reporting person continues to hold 145,355 shares of common stock directly after the reported transactions.

Filed: 2026-03-20

The reporting person, Claire Mazumdar, who is the Chief Executive Officer and a Director of Bicara Therapeutics Inc., has exercised a series of stock options and subsequently sold the underlying shares in multiple transactions from March 18-20, 2026.
The reported transactions were executed pursuant to a Rule 10b5-1 trading plan, indicating a pre-planned strategy for managing the insider's equity holdings.
The sale prices for the shares range from $18.73 to $19.26, suggesting the insider is taking advantage of the current market value of the company's stock.

Filed: 2026-03-17

Ryan Cohlhepp, the President and COO of Bicara Therapeutics, exercised 8,000 stock options and immediately sold 12,500 shares of the company's common stock on March 16, 2026.
The sale transactions were executed pursuant to a Rule 10b5-1 trading plan, indicating pre-planned and potentially non-discretionary nature of the transactions.
Cohlhepp's ownership of Bicara's common stock decreased from 213,141 shares to 200,641 shares as a result of the transactions.

Filed: 2026-03-11

Claire Mazumdar, the CEO of Bicara Therapeutics, has exercised stock options and sold a portion of her shares, indicating potential confidence in the company's future prospects.
The stock sale was executed pursuant to a pre-planned 10b5-1 trading plan, suggesting a strategic and disciplined approach to managing her holdings.
The significant number of shares still held by the CEO (over 339,000) suggests continued alignment with long-term shareholder interests.

Filed: 2026-03-02

RA Capital Management, L.P. and its affiliated funds have acquired a significant stake of over 7.2 million shares (around 10%) in Bicara Therapeutics Inc. (BCAX), indicating strong confidence in the company's prospects.
The filing reveals that RA Capital has purchased an additional 300,000 shares of BCAX at $16 per share, further increasing its stake in the company.
The presence of RA Capital, a prominent healthcare-focused investment firm, on Bicara's board of directors suggests the potential for strategic guidance and support for the company's development.

Filed: 2026-02-27

The reporting person, Ryan Cohlhepp, who is the President and COO of Bicara Therapeutics Inc. (BCAX), exercised 3,108 stock options and then sold 3,631 shares of the company's common stock in multiple transactions.
The transactions were executed pursuant to a Rule 10b5-1 trading plan that was adopted on February 12, 2025, indicating a pre-planned strategy for the insider's trading activity.
The reporting person continues to hold a substantial number of shares (209,641) in the company, suggesting ongoing confidence in the business.

Filed: 2026-02-04

Ryan Cohlhepp, the President and COO of Bicara Therapeutics, acquired 300,000 stock options, indicating his confidence in the company's future.
The options have a 10-year expiration period and vest over 16 quarters, suggesting a long-term commitment from Cohlhepp.
The exercise price of $16.76 per share is at the market price, aligning Cohlhepp's interests with those of other shareholders.

Filed: 2026-02-04

Insider Claire Mazumdar, the CEO of Bicara Therapeutics, has been granted a stock option to acquire 450,000 shares of the company's common stock, vesting over 4 years.
The exercise price of the stock option is $16.76 per share, indicating the company's valuation and the CEO's confidence in the company's future performance.
The significant size of the stock option grant suggests the CEO's long-term commitment to the company and alignment with shareholder interests.

Filed: 2026-02-04

David Raben, the Chief Medical Officer of Bicara Therapeutics, acquired 100,000 stock options with an exercise price of $16.76, vesting over 4 years. This indicates his confidence in the company's long-term prospects.
The timing of the option grant, in February 2026, suggests the company may be making progress on its drug development pipeline or achieving key milestones.
Insider transactions like this can provide insights into management's views on the company's future performance and growth potential.

Filed: 2026-02-04

Ivan Hyep, the Chief Financial Officer of Bicara Therapeutics Inc., has been granted 125,000 stock options with an exercise price of $16.76 and a 10-year expiration date. This indicates the company is incentivizing its executive leadership to drive long-term growth and value creation.
The stock options vest over 4 years in 16 equal quarterly installments, aligning Hyep's interests with those of shareholders and providing him with a stake in the company's future performance.
Insider transactions can provide insights into management's confidence in the company's outlook. The grant of these options suggests the CFO believes Bicara Therapeutics has promising prospects for the future.

Filed: 2026-02-04

Lara Meisner, the Chief Legal Officer of Bicara Therapeutics Inc. (BCAX), has been granted a stock option to purchase 90,000 shares of the company's common stock.
The option has an exercise price of $16.76 per share and vests in 16 equal quarterly installments over the next 4 years, subject to Meisner's continued service.
This award suggests that the company is incentivizing its executive team and aligning their interests with shareholders through equity-based compensation.

Other reports for Bicara Therapeutics Inc.

Annual Report Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.